Recent Company News

• 11:08 PM ET Jul 02, 2025
  

  ZAI Lab trading higher over +5% in HK; positive outlook for bemarituzumab in gastric cancer (HK$29.35, +1.50)

• 10:51 PM ET Jun 16, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 09:07 AM ET Jun 30, 2025
  

  Zai Lab reports phase 3 trial of bemarituzumab in FGFR2B+ first-line gastric cancer meets primary OS endpoint at interim analysis ($34.74, 0.00)

• 04:03 AM ET Jun 23, 2025
  

  Ono Pharmaceutical, Vertex Pharmaceuticals to collaborate on povetacicept; terms undisclosed ($440.87, 0.00)

• 12:17 PM ET Jun 22, 2025
  

  StreetAccount Scorecard: Weekly performance of the FTSE China Index sectors (ending 20-Jun)

• 11:59 PM ET Jun 18, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 07:04 AM ET Jun 13, 2025
  

  Zai Lab presents new preclinical data for ZL-1503 for the treatment of Atopic dermatitis at EAACI Congress 2025 ($43.03, 0.00)

• 06:51 PM ET Jun 12, 2025
  

  Incyte reports primary results from the Phase 3 POD1UM-303/InterAACT 2 trial published in The Lancet ($69.22, 0.00)